• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

SRI wins $150m grant to develop HIV prevention products

December 7, 2016 By Sarah Faulkner

SRI wins $150m grant to develop HIV prevention productsSRI International said today that it landed a $150 million contract from the National Institutes of Health‘s National Institute of Allergy and Infectious Diseases and the Division of AIDS to support the development of HIV microbicides and other pre-exposure agents. According to the 7-year deal, the research institute will provide preclinical product development services for non-vaccine HIV-prevention products that result from studies or collaborations with companies and organizations.

SRI Biosciences, a division of SRI International, will manufacture and characterize drug products to support promising microbicide and pre-exposure agents through preclinical studies. It will also give support for the required regulatory activities to move products along into clinical testing.

In 2010, the Menlo Park, Calif.-based think tank helped support the development of an HIV-prevention microbicide bioadhesive gel, funded by another NIAID grant.

“Since the early 2000s, researchers at SRI International have been involved in drug development activities to help move many microbicides, PrEP agents, and multipurpose prevention technologies through IND-enabling studies,” Gita Shankar, director of formulations R&D for SRI Biosciences’ Center for Pharmaceutical and Chemical Technologies, said in prepared remarks. “We are very pleased to be given an opportunity to contribute to the acceleration of promising HIV products into clinical testing and the creation of a sustainable pipeline of prevention products and strategies.”

Filed Under: Clinical Trials, Discovery, Featured, Food & Drug Administration (FDA), Funding Roundup, Preclinical Trials, Research & Development Tagged With: National Institutes of Health, SRI International

IN CASE YOU MISSED IT

  • Tandem Diabetes Care wins CE mark for Mobi insulin pump with Control-IQ+ technology
  • Glooko adds chief strategy officer to chief medical officer’s title
  • Cordis launches 10,000-patient registry for drug-eluting balloon
  • Senseonics opens $50M public offering, $25M private placement with Abbott
  • Study links Abbott CGM use to lower risk of hospitalizations due to heart complications

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS